(Q37205638)

English

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

scientific article published on June 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study (English)

1 reference

Europe PubMed Central

18 August 2017

multicenter clinical trial

0 references

Behçet's disease

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

1

object named as

Toshifumi Hibi

1 reference

Europe PubMed Central

18 August 2017

author name string

Shunsei Hirohata

2

1 reference

Europe PubMed Central

18 August 2017

Hirotoshi Kikuchi

3

1 reference

Europe PubMed Central

18 August 2017

Ukihide Tateishi

4

1 reference

Europe PubMed Central

18 August 2017

Noriko Sato

5

1 reference

Europe PubMed Central

18 August 2017

Kunihiko Ozaki

6

1 reference

Europe PubMed Central

18 August 2017

Kazuoki Kondo

7

1 reference

Europe PubMed Central

18 August 2017

Yoshiaki Ishigatsubo

8

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

1 June 2016

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

95

1 reference

Europe PubMed Central

18 August 2017

24

1 reference

Europe PubMed Central

18 August 2017

e3863

1 reference

Europe PubMed Central

18 August 2017

Diagnosis and management of intestinal Behçet's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

New insights into the pathogenesis of Behçet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Behcet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

6 September 2017

Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

14 September 2017

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

28 September 2017

Effect of infliximab in progressive neuro-Behçet's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

26 June 2018

Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

26 June 2018

Behçet disease: evolution of clinical manifestations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

3 September 2018

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

3 September 2018

Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

3 September 2018

Quality of life and life satisfaction in patients with Behçet's disease: relationship with disease activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

3 September 2018

Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

3 September 2018

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

3 September 2018

Behçet's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998455

20 October 2018

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in the treatment of intestinal Behcet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27310969

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MD.0000000000003863

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37205638&oldid=1694443417"